Capricor Plunges 14.84% on Mid-Cycle Review
Monday, May 5, 2025 8:26 am ET
1min read On May 5, 2025, Capricor's stock experienced a significant drop of 14.84% in pre-market trading, reflecting a notable decline in investor sentiment.
Capricor Therapeutics recently announced the completion of its mid-cycle review, a critical milestone in its ongoing clinical trials. This development is part of the company's broader strategy to advance its therapeutic pipeline and bring innovative treatments to market.
Additionally, capricor reported its Q3 2024 earnings, posting a revenue of $2.3 million. While this figure may not be groundbreaking, it underscores the company's efforts to generate revenue through its existing products and services, providing a foundation for future growth.
Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.
